Autolus Therapeutics plc
AUTLNASDAQHealthcare● Active
$1.45
$-0.08(-5.23%)
Market Cap$385907750
P/E Ratio—
52W High$2.7
52W Low$1.175
Autolus Therapeutics plc (AUTL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AUTL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $75.56M | $10.12M | $1.70M | $6.19M | $1.51M |
| Cost of Revenue | $96.59M | $141.02M | $0.00M | $0.00M | $0.00M |
| Gross Profit | ($21.03M) | ($130.90M) | $1.70M | $6.19M | $1.51M |
| Gross Margin %(computed) | -27.83% | — | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $128.59M | $158.14M | $130.48M | $117.35M | $110.84M |
| G&A Expenses | $0.00M | $0.00M | $46.74M | $31.90M | $31.86M |
| Total Operating Expenses | $260.41M | $110.53M | $181.40M | $149.09M | $141.88M |
| Operating Income | ($281.44M) | ($241.43M) | ($179.70M) | ($142.89M) | ($140.37M) |
| Operating Margin %(computed) | -372.45% | — | — | — | — |
| Interest Income | $19.02M | $32.35M | $13.51M | $1.71M | $0.26M |
| Interest Expense | $36.76M | $9.29M | $45.07M | $8.90M | $1.10M |
| Income Before Tax | ($296.85M) | ($219.13M) | ($208.40M) | ($148.57M) | ($142.04M) |
| Income Tax Expense | ($8.65M) | $1.53M | ($0.02M) | $0.27M | $0.06M |
| Net Income | ($288.20M) | ($220.66M) | ($208.38M) | ($148.84M) | ($142.10M) |
| Net Margin %(computed) | -381.40% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.08 | $-0.87 | $-1.20 | $-1.57 | $-1.97 |
| Wtd Avg Shares | 266.14M | 255.16M | 173.94M | 94.99M | 72.08M |
| EBITDA | ($271.60M) | ($233.07M) | ($156.77M) | ($132.24M) | ($132.47M) |
| EBITDA Margin %(computed) | -359.43% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Autolus Therapeutics plc data
About Autolus Therapeutics plc (AUTL) Income Statement
Autolus Therapeutics plc (AUTL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AUTL reported revenue of $0.08B, gross profit of ($0.02B) (gross margin -27.83%), and net income of ($0.29B) — a net profit margin of -381.40%.
Frequently asked questions
AUTL · 4 questionsAutolus Therapeutics plc (AUTL) reported revenue of $0.08B for 2025, up 646.7% year-over-year.
AUTL revenueAUTL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08